AlgiPharma has successfully completed six clinical trials in Cystic Fibrosis, including a drug deposition study (NCT00970346; NCT01465529; NCT01991028; NCT02453789; NCT02157922; NCT03822455). Additional details about clinical trials are available at www.clinicaltrials.gov
Our drug candidate has proven to be safe and well tolerated for inhalation use (+175 safety population).
Our drug candidate for Cystic Fibrosis has Orphan Drug designation from both the European Medicines Agency and the FDA.
AlgiPharma boasts a comprehensive preclinical toxicology portfolio supporting an exemplary safety profile for inhalation administration.